A new approach to preventing heart and circulatory diseases has been bolstered by landmark trial data showing that potent cholesterol-lowering injections can prevent heart attacks and strokes in patients considered at moderate, rather than extreme, risk. The findings challenge a long-standing treatment paradigm and are set to intensify the debate over how aggressively the UK should tackle cholesterol.
Trial demonstrates early intervention benefit
The results come from a subgroup analysis of the large VESALIUS-CV trial, involving 3,655 high-risk patients with type 2 diabetes but no known atherosclerosis—meaning they had not yet suffered a heart attack or stroke. The trial tested the injectable drug evolocumab as an addition to standard therapy, which included statins and another tablet called ezetimibe.
Over a median follow-up of nearly five years, adding the injection slashed the risk of major cardiovascular events—including coronary heart disease death, heart attack, or ischaemic stroke—by 31%. The 5-year event rate was 5% for those on the injection, compared to 7.1% for those on placebo. This adds to evidence that for those at elevated risk, driving cholesterol levels far lower than current UK targets provides significant protection.
“For over a decade, intensive cholesterol‑lowering has been reserved for patients who already have cardiovascular disease,” said Dr Nicholas Marston, a cardiologist at the Mass General Brigham Heart and Vascular Institute in Boston, who led the trial. “These results demonstrate the benefit of intensive lowering of cholesterol earlier and should change how we think about the prevention of heart attacks, strokes, and heart disease.”
How the new injections work
The trial drug, evolocumab, belongs to a class known as PCSK9 inhibitors, seen as a more aggressive therapy than standard statin tablets. Their mechanism is distinct and more potent. While statins work by reducing the liver’s production of cholesterol, PCSK9 inhibitors work by blocking a specific protein (PCSK9). This blockade leads to a surge in the number of LDL receptors on the liver’s surface, which then act like magnets to pull significantly more “bad” LDL cholesterol out of the bloodstream for disposal.
This process can lower LDL cholesterol levels by approximately 60%, compared to the 30-50% reduction typically achieved with statins. When combined with statins, the effect is even more powerful, as demonstrated in the trial where evolocumab lowered levels by a further 50% in patients already on medication.
For patients who cannot tolerate statins due to side effects like muscle pain, other oral alternatives exist. Ezetimibe blocks cholesterol absorption in the gut, while bempedoic acid—activated only in the liver—inhibits cholesterol synthesis there and may cause fewer muscle issues. Used together, these tablets can lower LDL by roughly 35%.
Conservative UK criteria under scrutiny
Despite this evidence, the UK’s use of these advanced therapies lags behind international peers, constrained by strict guidelines and cost considerations. The National Institute for Health and Care Excellence (NICE) currently recommends PCSK9 inhibitors only for specific groups: those with familial hypercholesterolaemia or established cardiovascular disease whose cholesterol remains high on maximum oral therapy, or who cannot tolerate statins.
In practice, NHS guidance states the injections may only be given if someone’s LDL cholesterol remains above 3.5 millimoles per litre (mmol/L) despite taking the highest tolerated doses of statins and ezetimibe. The general LDL target for high-risk patients in the UK is 2.0 mmol/L.
These limits are described as “extremely conservative” by Professor Ian Graham, a cardiologist at Trinity College Dublin. They contrast sharply with international standards; guidelines from the European Society of Cardiology and the American Heart Association recommend targets below 1.8 mmol/L, and ideally below 1.4 mmol/L, for high-risk patients.
Cost is a major factor. Evolocumab carries a significant price tag—its UK list price was approximately £4,400 per year in 2016. NICE, as the UK’s cost-effectiveness body, has historically required substantial price discounts for PCSK9 inhibitors to meet its thresholds for widespread NHS use.
US guidelines push for earlier, tougher action
The transatlantic divide in approach was highlighted earlier this month when new guidelines from 11 US medical societies recommended people start having their cholesterol measured from age 30. They also advocate using higher doses of statins or other drugs to drive LDL down to 1.4 mmol/L.
“I think we should be considering following the American advice now,” said Dr Joseph Cheriyan, a heart researcher at the University of Cambridge. “High LDLs over a lifetime increase your risk. We need to make sure everybody gets their cholesterol down as quickly as possible and as low as possible.”
UK specialists believe the new trial data will shift practice. Professor Naveed Sattar, a heart specialist at the University of Glasgow who was involved in the trial, anticipates it will lead to increased use of cholesterol-lowering therapy overall. “I think this paper will lead to a few more people getting [injections]. But the biggest hit is going to be more people thinking: ‘Instead of just giving a statin, I should also be thinking about ezetimibe’,” he said.
The study, published in the journal JAMA, underscores a central tension in modern healthcare: balancing the proven benefits of earlier, more intensive treatment with the economic realities of funding a national health service. For now, the UK’s criteria remain firmly anchored to the latter.